More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia

Eitemau Tebyg

• Acute myeloid leukemia: current progress and future directions
  gan: Kantarjian, Hagop, et al.
  Cyhoeddwyd: (2021)
• Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
  gan: Takahashi, Koichi, et al.
  Cyhoeddwyd: (2016)
• TP53 mutations in newly diagnosed Acute Myeloid Leukemia –Clinico-molecular characteristics, response to therapy, and outcomes
  gan: Kadia, Tapan M., et al.
  Cyhoeddwyd: (2016)
• Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
  gan: Montalban-Bravo, Guillermo, et al.
  Cyhoeddwyd: (2020)
• Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia
  gan: Short, Nicholas J., et al.
  Cyhoeddwyd: (2020)